Research advances in chimeric antigen receptor-modified T-cell therapy (Review)

xlomafota13 shared this article with you from Inoreader Research advances in chimeric antigen receptor-modified T-cell therapy (Review) Via Experimental and therapeutic medicine Exp Ther Med. 2021 May;21(5):484. doi: 10.3892/etm.2021.9915. Epub 2021 Mar 16. ABSTRACT Chimeric antigen receptor (CAR)-modified T-cells are T-cells that have been genetically engineered to express CAR molecules to target specific surface antigens on tumor cells. CAR T-cell therapy, a novel cancer immunotherapy, has been attracting increasing attention, since it exhibited notable efficacy in the treatment of hematological tumors in clinical trials. However, for this type of therapy, challenges must be overcome in the treatment of solid tumors. Furthermore, certain side effects associated with CAR T-cell therapy, including cytokine release syndrome, immune effector cell-related neurotoxicity syndrome, tumor lysis syndrome and on-target off-tumor toxicity, must be taken into consideration. The present study provides a systematic review of the principle, clinical application, current challenges, possible solutions and future perspectives for CAR T-cell therapy. PMID:33790993 | PMC:PMC8005741 | DOI:10.3892/etm.2021.9915 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.